publication date: Jun. 12, 2015
Lenvatinib Launched in U.K. For Advanced Thyroid Cancer
Lenvima (lenvatinib) launched in the U.K. as a treatment option for adult patients with progressive locally advanced or metastatic, differentiated (papillary, follicular, Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Lenvatinib demonstrated significantly prolonged progression-free survival in RAI refractory DTC versus placebo. Lenvatinib showed a median 18.3 months progression free survival PFS versus 3.6 months for placebo (HR=0.21; 99% CI, 0.14-0.31; p<0.0001).
In addition, the study underlines the rapid response of lenvatinib, with a median time to first objective response of two months.
The SELECT study, published in the New England Journal of Medicine, is a randomized, double-blind, multicenter trial for people with progressive radioactive iodine refractory differentiated thyroid cancer (n=392). Lenvatinib significantly improved objective response rate versus placebo (64.8 vs. 1.5 percent; p<0.0001).
For lenvatinib, the most common treatment related adverse events were hypertension, diarrhea, fatigue, decreased appetite, decreased weight, and nausea.
“The launch of Lenvima represents great news for both Eisai and for patients who will now have access to this significant new treatment. Lenvima is a drug that was developed in the UK, will be manufactured in the UK and has now been launched first in the UK, something we at Eisai are very proud of,” said Gary Hendler, president and CEO of Eisai EMEA and president of the Eisai Oncology Global Business Unit.
Lenvatinib is an oral molecular tri-specific targeted therapy that possesses a potent selectivity and a binding mode different to other tyrosine kinase inhibitors. Lenvatinib simultaneously … Continue reading 41-23 Lenvatinib Launched in U.K. For Advanced Thyroid Cancer
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.